Ibnsina Pharma

CASE:ISPH Stock Report

Market Cap: ج.م10.7b

Ibnsina Pharma Valuation

Is ISPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ISPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ج.م8.05
Fair Value
32.1% overvalued intrinsic discount
3
Number of Analysts

Below Fair Value: ISPH (EGP10.63) is trading above our estimate of fair value (EGP8.05)

Significantly Below Fair Value: ISPH is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ISPH?

Key metric: As ISPH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ISPH. This is calculated by dividing ISPH's market cap by their current earnings.
What is ISPH's PE Ratio?
PE Ratio15.2x
Earningsج.م702.99m
Market Capج.م10.72b

Price to Earnings Ratio vs Peers

How does ISPH's PE Ratio compare to its peers?

The above table shows the PE ratio for ISPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average44.7x
CLHO Cleopatra Hospitals GroupE
25.9x26.93%ج.م18.0b
AMES Alexandria New Medical Center
118.9xn/aج.م6.0b
NINH Nozha International Hospital
15.9xn/aج.م2.3b
2393 Nippon Care Supply
18.1xn/aJP¥37.4b
ISPH Ibnsina Pharma
15.2x27.81%ج.م10.7b

Price-To-Earnings vs Peers: ISPH is good value based on its Price-To-Earnings Ratio (15.2x) compared to the peer average (44.7x).

Price to Earnings Ratio vs Industry

How does ISPH's PE Ratio compare vs other companies in the Global Healthcare Industry?

14 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ISPH 15.2xIndustry Avg. 19.4xNo. of Companies85PE01632486480+
14 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ISPH is good value based on its Price-To-Earnings Ratio (15.2x) compared to the Global Healthcare industry average (19.4x).

Price to Earnings Ratio vs Fair Ratio

What is ISPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ISPH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.2x
Fair PE Ratio19.4x

Price-To-Earnings vs Fair Ratio: ISPH is good value based on its Price-To-Earnings Ratio (15.2x) compared to the estimated Fair Price-To-Earnings Ratio (19.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ISPH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentج.م10.63
ج.م15.90
+49.58%
6.73%ج.م17.10ج.م14.50n/a3
Nov ’26ج.م11.22
ج.م17.08
+52.18%
13.10%ج.م20.60ج.م14.50n/a4
Oct ’26ج.م11.37
ج.م17.08
+50.18%
13.10%ج.م20.60ج.م14.50n/a4
Sep ’26ج.م10.39
ج.م17.08
+64.34%
13.10%ج.م20.60ج.م14.50n/a4
Aug ’26ج.م10.00
ج.م17.08
+70.75%
13.10%ج.م20.60ج.م14.50n/a4
Jul ’26ج.م9.09
ج.م15.73
+72.99%
23.02%ج.م20.60ج.م10.70n/a4
Jun ’26ج.م9.16
ج.م13.83
+50.93%
31.28%ج.م20.60ج.م9.50n/a4
May ’26ج.م8.81
ج.م11.72
+33.03%
41.79%ج.م20.60ج.م5.80n/a5
Apr ’26ج.م8.87
ج.م9.42
+6.20%
22.02%ج.م12.00ج.م5.80n/a5
Mar ’26ج.م6.64
ج.م8.62
+29.82%
19.18%ج.م10.70ج.م5.80n/a5
Feb ’26ج.م6.76
ج.م8.62
+27.51%
19.18%ج.م10.70ج.م5.80n/a5
Jan ’26ج.م7.00
ج.م8.62
+23.14%
19.18%ج.م10.70ج.م5.80n/a5
Dec ’25ج.م6.77
ج.م6.76
-0.22%
28.58%ج.م9.10ج.م4.12ج.م11.054
Nov ’25ج.م5.20
ج.م6.34
+21.92%
32.63%ج.م9.10ج.م4.12ج.م11.223
Oct ’25ج.م5.25
ج.م4.96
-5.52%
16.94%ج.م5.80ج.م4.12ج.م11.372
Sep ’25ج.م3.37
ج.م4.84
+43.62%
14.60%ج.م5.80ج.م4.12ج.م10.393
Aug ’25ج.م2.95
ج.م4.84
+64.18%
14.52%ج.م5.80ج.م4.13ج.م10.003
Jul ’25ج.م2.93
ج.م4.84
+65.30%
14.52%ج.م5.80ج.م4.13ج.م9.093
Jun ’25ج.م2.62
ج.م4.63
+76.81%
15.33%ج.م5.80ج.م4.00ج.م9.164
May ’25ج.م2.43
ج.م4.63
+90.64%
15.33%ج.م5.80ج.م4.00ج.م8.814
Apr ’25ج.م2.50
ج.م4.63
+85.30%
15.33%ج.م5.80ج.م4.00ج.م8.874
Mar ’25ج.م3.80
ج.م4.63
+21.84%
15.37%ج.م5.80ج.م4.00ج.م6.644
Feb ’25ج.م3.00
ج.م3.43
+14.33%
24.72%ج.م4.12ج.م2.00ج.م6.764
Jan ’25ج.م3.14
ج.م3.43
+9.24%
24.72%ج.م4.12ج.م2.00ج.م7.004
Dec ’24ج.م2.70
ج.م3.43
+27.04%
24.72%ج.م4.12ج.م2.00ج.م6.774
ج.م15.9
Fair Value
33.1% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/04 23:05
End of Day Share Price 2025/12/04 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ibnsina Pharma is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Marina MikhailCI Capital Research
Ahmed MoatazEFG-Hermes Research
Marina MakeenPharos Research